clinical trial

FDA grants J&J's Rybrevant Faspro breakthrough designation for HPV-negative head and neck cancer, potentially accelerating patient access to this new treatment option.

CervoMed's neflamapimod selected for UK's accelerated EXPERTS-ALS trial platform. The drug will be evaluated in 35-80 ALS patients over 18-24 weeks.

HCW Biologics raised $1.5M through a unit offering and seeks shareholder approval to reduce warrant exercise price from $2.41 to $0.6055 per share.

REGENXBIO faces class action lawsuit alleging false statements about RGX-111 gene therapy trial results, covering securities purchased between February 2022 and January 2026.

Teva and Sanofi report positive Phase 3 results for duvakitug IBD treatment, with over 55% of patients meeting efficacy endpoints. Stock rises 2.85%.

Eli Lilly's Retevmo shows significant benefits in early-stage lung cancer, reducing recurrence risk in Phase 3 trial. Positive results may expand the drug's use beyond advanced-stage disease.

Inventiva raises $172.5M, boosting cash position to €99.3M and extending runway through mid-2027 to fund MASH therapy development.

Law firm sues uniQure for allegedly misrepresenting gene therapy trial status and FDA approval timeline, causing stock to surge 250% then fall 49% after FDA reversal.

Vistagen faces securities class action over alleged misleading statements about drug fasedienol. Investors who purchased stock April 2024-December 2025 can join by March 16, 2026 deadline.